AMGN · Company research
Amgen Inc (AMGN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
51records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know | Amgen has attracted investor attention with a +12.2% return over the past month, outperforming the S&P 500's +1.5% gain. The company shows solid fundamentals with expected earnings growth of +5% for the current fiscal year and +7.1% for the next year, along with consistent revenue growth projections of +5.7% and +3.2% respectively. However, with a Zacks Rank #3 (Hold) rating and a neutral valuation grade of C, the stock is expected to perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | neutral | 0 | 1 |
| Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus | The U.S. economy showed mixed signals with rising inflation (3.7% headline, 2.6% core) and geopolitical tensions pressuring markets. The Nasdaq fell 4.1% while the Dow gained 0.29%, reflecting investor preference for blue-chip stocks over tech. Despite market uncertainty, Zacks' research-driven rating systems demonstrated strong performance, with Valero Energy gaining 29.7% post-upgrade, Palantir surging 40.5% over 12 weeks, and the Zacks Rank #1 portfolio outperforming the S&P 500 by 3.9 percentage points year-to-date. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider | Amgen (AMGN) closed at $434.03, up 1.86%, outperforming the S&P 500. The stock has gained 13.22% over the past month. Upcoming Q3 2026 earnings are expected on November 3 with an EPS of $5.72 (+1.42% YoY) and revenue of $9.93 billion (+3.94% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.57, trading at a discount to its industry average. However, the Medical - Biomedical and Genetics industry ranks 153rd out of 250+ industries. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider | Amgen (AMGN) closed at $434.03, up 1.86%, outperforming the S&P 500. The stock has gained 13.22% over the past month. Upcoming Q3 2026 earnings are expected on November 3 with an EPS of $5.72 (+1.42% YoY) and revenue of $9.93 billion (+3.94% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.57, trading at a discount to its industry average. However, the Medical - Biomedical and Genetics industry ranks 153rd out of 250+ industries. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| Amgen Inc. $AMGN Stock Acquired by State of Alaska Department of Revenue - MarketBeat | Amgen Inc. $AMGN Stock Acquired by State of Alaska Department of Revenue MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Amgen Inc. $AMGN Stock Sold by WealthPlan Investment Management LLC - MarketBeat | Amgen Inc. $AMGN Stock Sold by WealthPlan Investment Management LLC MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow - 24/7 Wall St. | AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 15, 2026 | neutral | 0 | 0.6 |
| Amgen Inc Stock (AMGN) Moved Up by 3.01% on Oct 15: A Full Analysis - TradingKey | Amgen Inc Stock (AMGN) Moved Up by 3.01% on Oct 15: A Full Analysis TradingKey | View source ↗ | TradingKey | Oct 15, 2026 | neutral | 0 | 0.6 |
| NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? - Stocktwits | NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains? - Stocktwits | These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In? - Yahoo Finance | Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled - TradingKey | Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled TradingKey | View source ↗ | TradingKey | Oct 14, 2026 | neutral | 0 | 0.6 |
| Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum - Quiver Quantitative | Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 14, 2026 | neutral | 0 | 0.6 |
| Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? | Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.333 | 1 |
| Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? | Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.333 | 1 |
| J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down | Johnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down | Johnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition. MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.75 | 1 |
| Here's Why Amgen (AMGN) is a Strong Momentum Stock | Amgen (AMGN), a major biotech company, receives a #3 (Hold) rating from Zacks with a B VGM Score. While the company faces declining sales from older drugs due to biosimilar competition and recent patent expirations for key products Prolia and Xgeva in 2025, momentum investors should note the stock's 9.5% gain over the past four weeks. Six analysts have raised earnings estimates in the last 60 days, with the consensus estimate increasing to $22.94 per share. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Here's Why Amgen (AMGN) is a Strong Momentum Stock | Amgen (AMGN), a major biotech company, receives a #3 (Hold) rating from Zacks with a B VGM Score. While the company faces declining sales from older drugs due to biosimilar competition and recent patent expirations for key products Prolia and Xgeva in 2025, momentum investors should note the stock's 9.5% gain over the past four weeks. Six analysts have raised earnings estimates in the last 60 days, with the consensus estimate increasing to $22.94 per share. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 1 |
| Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? - Yahoo Finance | Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth - Simply Wall Street | Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News - Yahoo Finance | Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) Laps the Stock Market: Here's Why | Amgen (AMGN) closed at $414.87, up 1.82%, outperforming the S&P 500's 0.6% gain. The biotech giant has risen 6.53% over the past month. Upcoming earnings are projected at $5.7 per share with revenue expected at $9.92 billion. Full-year estimates suggest $22.94 EPS and $38.83 billion revenue, representing 5.04% and 5.65% growth respectively. However, the stock holds a Zacks Rank #3 (Hold) with a recent 0.13% downward EPS estimate revision. Trading at a Forward P/E of 17.76, it trades at a discount to the industry average of 23.15. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Amgen Inc. $AMGN Shares Acquired by Wedmont Private Capital - MarketBeat | Amgen Inc. $AMGN Shares Acquired by Wedmont Private Capital MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| UBS Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat | UBS Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens | Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.667 | 1 |
| A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens | Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.667 | 1 |
| J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? | Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.333 | 1 |
| J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? | Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.333 | 1 |
| Amgen Inc. $AMGN Stock Position Raised by Mn Services Vermogensbeheer B.V. - MarketBeat | Amgen Inc. $AMGN Stock Position Raised by Mn Services Vermogensbeheer B.V. MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Amgen Inc. $AMGN Shares Acquired by Farther Finance Advisors LLC - MarketBeat | Amgen Inc. $AMGN Shares Acquired by Farther Finance Advisors LLC MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued - Simply Wall Street | Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| What Would It Take For Amgen Stock To Move Higher? - Trefis | What Would It Take For Amgen Stock To Move Higher? Trefis | View source ↗ | Trefis | Oct 8, 2026 | neutral | 0 | 0.6 |
| Stock Market News for Oct 8, 2026 | U.S. stock markets closed higher on Wednesday with the Dow rising 0.7%, Nasdaq and S&P 500 each gaining 0.2%. Federal Reserve officials project another rate hike by end of 2026 but remain divided on timing amid economic uncertainty. Consumer credit growth fell short of expectations in August. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Stock Market News for Oct 8, 2026 | U.S. stock markets closed higher on Wednesday with the Dow rising 0.7%, Nasdaq and S&P 500 each gaining 0.2%. Federal Reserve officials project another rate hike by end of 2026 but remain divided on timing amid economic uncertainty. Consumer credit growth fell short of expectations in August. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Amgen (AMGN) Advances While Market Declines: Some Information for Investors | Amgen stock gained 2.6% to close at $413.08, outperforming the broader market decline. The biotech giant is projected to report EPS of $5.69 (up 0.89% YoY) and revenue of $9.91 billion (up 3.68% YoY). For the full year, consensus estimates project earnings of $22.94 per share and revenue of $38.81 billion. Amgen holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 17.55, trading at a discount to its industry average. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| Top dow jones movers in Wednesday's session - ChartMill | Top dow jones movers in Wednesday's session ChartMill | View source ↗ | ChartMill | Oct 7, 2026 | neutral | 0 | 0.6 |
| Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis - TradingKey | Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis TradingKey | View source ↗ | TradingKey | Oct 7, 2026 | neutral | 0 | 0.6 |
| Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It | Amgen has recently been a trending stock, with shares down 7.8% over the past month compared to the S&P 500's +0.8% gain. The biotech company shows solid fundamentals with consistent earnings and revenue beat history, but the Zacks Rank #3 (Hold) rating suggests it may perform in line with the broader market in the near term. Current year earnings are expected to grow 5% with revenue growth of 5.6%, while the stock trades at par with peers based on valuation metrics. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It | Amgen has recently been a trending stock, with shares down 7.8% over the past month compared to the S&P 500's +0.8% gain. The biotech company shows solid fundamentals with consistent earnings and revenue beat history, but the Zacks Rank #3 (Hold) rating suggests it may perform in line with the broader market in the near term. Current year earnings are expected to grow 5% with revenue growth of 5.6%, while the stock trades at par with peers based on valuation metrics. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance | Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Amgen (AMGN) Stock Dips While Market Gains: Key Facts | Amgen (AMGN) declined 3.38% in the latest trading session, underperforming the broader market. While the company's upcoming earnings are projected to show modest growth with EPS of $5.69 (+0.89% YoY) and revenue of $9.91 billion (+3.68% YoY), analyst estimates have slightly declined by 0.15% over the past month. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.38, trading at a discount to its industry average, though its PEG ratio of 3.04 exceeds the industry average of 1.91. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Amgen (AMGN) Stock Dips While Market Gains: Key Facts | Amgen (AMGN) declined 3.38% in the latest trading session, underperforming the broader market. While the company's upcoming earnings are projected to show modest growth with EPS of $5.69 (+0.89% YoY) and revenue of $9.91 billion (+3.68% YoY), analyst estimates have slightly declined by 0.15% over the past month. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.38, trading at a discount to its industry average, though its PEG ratio of 3.04 exceeds the industry average of 1.91. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance | Amgen (AMGN) Stock Dips While Market Gains: Key Facts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win | At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win | At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks - Yahoo Finance | Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| Why Amgen (AMGN) Stock Is Trading Up Today - StockStory | Why Amgen (AMGN) Stock Is Trading Up Today StockStory | View source ↗ | StockStory | Aug 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.